

GP 1614  
BOX PATENT

Attorney Docket No. 24218

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

ZENNER, Hans Peter; RUPPERSBERG, J. Peter; LÖWENHEIM, Hubert

Serial No. 09/530,693

Filed: July 3, 2000 (102(e) date)

For: USE OF VASOPRESSIN ANTAGONISTS



RECEIVED

AUG 29 2000

TECH CENTER 1600/2900

TRANSMITTAL LETTER

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- (1) Transmittal Letter
- (2) Information Disclosure Statement
- (3) Information Disclosure Statement Transmittal Letter
- (4) PTO Form 1449 with 8 references
- (5) Copy of German Search Report dated April 30, 1998
- (6) Copy of PCT/ISA/210 International Search Report

The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account No. 14-0112.

Respectfully submitted,

NATH & ASSOCIATES PLLC

By:

  
Gary M. Nath  
Registration No. 26,965  
Jerald L. Meyer  
Registration No. 41,194  
Customer No. 20529

Date: August 25, 2000  
NATH & ASSOCIATES PLLC  
1030 15<sup>th</sup> Street NW - 6<sup>th</sup> Floor  
Washington, D.C. 20005  
GMN/JLM/dd:IDS

**BOX PATENT**  
Attorney Docket No. 24218  
*DX/le*

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

ZENNER, Hans Peter; RUPPERSBERG, J. Peter; LÖWENHEIM, Hubert

Serial No. 09/530,693

Filed: July 3, 2000 (102(e) date)

For: **USE OF VASOPRESSIN ANTAGONISTS**



**INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner  
of Patents  
Washington, D.C. 20231

Sir:

Pursuant to Applicant's duty of disclosure under 37 C.F.R. §§1.56 and 1.97-1.99, the documents listed on the attached Form PTO-1449 are being brought to the attention of the Examiner in charge of the above-identified application. No fee is required for this submission because it is submitted before the mailing of the First Office Action on the merits.

Copies of the documents are attached herewith with a completed Form PTO-1449. The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449



with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account No. 14-0112.

Respectfully submitted,

**NATH & ASSOCIATES PLLC**

Date: August 25, 2000

---



Gary M. Nath  
Reg. No. 26,965  
Jerald L. Meyer  
Registration No. 41,194  
Customer No. 20529

NATH & ASSOCIATES PLLC  
1030 15<sup>th</sup> Street, NW 6<sup>th</sup> - Floor  
Washington, D.C. 20005  
Tel: (202) 775-8383  
Fax: (202) 775-8396  
(GMN/JLM/dd IDS)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re Application of:

ZENNER, Hans Peter; RUPPERSBERG, J. Peter; LÖWENHEIM, Hubert

Serial No. 09/530,693

Filed: July 3, 2000 (102(e) date)

For: USE OF VASOPRESSIN ANTAGONISTS



RECEIVED

AUG 29 2000

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Assistant Commissioner of Patents  
Washington, D.C. 20231  
S I R :

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. §1.97-1.98. Please note the following particulars:

[NOTE: One only of items a, b, c, and d must be checked.]

a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. §1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.

b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. §1.113, or a notice of allowance under 37 C.F.R. §1.311.

The enclosed statement is accompanied by [check one]:

i. a certification in part (e) below as specified in 37 C.F.R. §1.97(e), or

ii. a check in the amount of \$240.00 required by 37 C.F.R. §1.17(p).

c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. §1.113, or a notice of allowance under 37 C.F.R. §1.311, but before payment of the issue fee.

PETITION: It is requested that the information being submitted be considered. [NOTE: If box (c) is checked, the following two boxes must be checked.]

PETITION FEE: A check for \$130.00 required by 37 CFR §1.17(i)(1), is enclosed.

CERTIFICATION is attested to in box (e) below.

[ ] d. The enclosed statement is being filed pursuant to 37 C.F.R. §1.97(i), for placement in the file.

[ ] e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

[ ] I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,

or

[ ] I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or


[ ] Appropriate certification is attached.

[ x ] f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

Respectfully submitted,  
**NATH & ASSOCIATES PLLC**

Date: August 25, 2000

By:

  
Gary M. Nath  
Registration No. 26,965  
Jerald L. Meyer  
Registration No. 41,194  
Customer No. 20529

NATH & ASSOCIATES PLLC  
1030 15<sup>th</sup> Street, N.W., 6<sup>th</sup> Floor  
Washington, D.C. 20005  
Tel. (202) 775-8383  
Fax. (202) 775-8396  
GMN/JLMdd (IDS.HLN)

FORM PTO-1449			Atty Docket 24218	Serial No. 09/530,693			
INFORMATION DISCLOSURE CITATION AUG 25 2000			Applicant Zenner et al.				
			Filing Date 03 July 2000	Group Art Unit 1614			
<b>U. S. PATENT DOCUMENTS</b>							
Examiner Initial		Document Number	Issue Date	Name	Class	Sub-Class	Filing Date
	AA	5,095,003	03.10.92	Goetz et al.	514	9	10.23.90
<b>FOREIGN PATENT DOCUMENTS</b>							
		Document Number	Date	Country	Class	Sub-Class	Trans-lation
	AB	94/18975	01.09.94	WO			YES
<b>OTHER</b> (Including Author, Title, Date, Pertinent Pages, etc.)							
	AC	Mantione, C.R., et al., "A bradykinin (BK) <sub>1</sub> receptor antagonist blocks capsaicin-induced ear inflammation in mice" <u>Br. J. Pharmacol.</u> 1990 vol. 99 pp. 516-518					
	AD	Mori, N., et al., "The study of vasopressin receptors in the cochlea" <u>Chemical Abstracts</u> , Jan. 4, 1998 vol. 108, No. 1					
	AE	Yamamura, Y., et al., "Characterization of novel aquaretic agent OPC-31260, as an orally effective, nonpeptide vasopressin V <sub>2</sub> receptor antagonist" <u>Br. J. Pharmacol.</u> 1992 vol. 105, pp. 787-791					
	AF	Serradeil, C., et al., "Characterization of SR 121463A, a Highly Potent and Selective, Orally Active Vasopressin V <sub>2</sub> Receptor Antagonist" <u>J. Clin. Invest.</u> Dec. 1996 vol. 98, No. 12, pp. 2729-2738					
	AG	M. Manning et al. <u>Database Medline US National Library of Medicine (NLM)</u> , Accession no. 1549, Bethesda, Md, US					
	AH	Kitano, H., et al. "Vasopressin and oxytocin receptor mRNAs are expressed in the rat inner ear" <u>Neuro Report</u> July 1997, vol. 8 No 9-10, pp. 2289-2292					
Examiner				Date Considered			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							

**TRANSLATION AND MEANING OF LETTERS IN LEFT COLUMN OF GERMAN  
SEARCH REPORT**

Please note the remarks of the examiners in the first columns. The meaning of the letters in the left column is as follows:

- A technological background
- Y particularly relevant if combined with another document of the same category